Jun 14, 2022
Autor: Emerson Cestari Marino
Revista: Lancet Diabetes Endocrinol, Nat Med
Ref:
1) Pasquel FJ. Management of diabetes and hyperglycaemia in
the hospital. Lancet Diabetes Endocrinol. 2021
Mar;9(3):174-188.
2) Kosiborod MN. Dapagliflozin in patients with cardiometabolic risk factors hospitalised with COVID-19 (DARE-19): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Diabetes Endocrinol. 2021 Sep;9(9):586-594.
2) Kosiborod MN. Dapagliflozin in patients with cardiometabolic risk factors hospitalised with COVID-19 (DARE-19): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Diabetes Endocrinol. 2021 Sep;9(9):586-594.
3) Voors AA. The SGLT2 inhibitor empagliflozin in patients
hospitalized for acute heart failure: a multinational randomized
trial. Nat Med. 2022 Mar;28(3):568-574.